Penetrative Ionic Organic Molecular Cage Nanozyme for the Targeted Treatment of Keratomycosis
Hongwei Wang,Fangying Song,Xia Qi,Xiaoyu Zhang,Li Ma,Depeng Shi,Xiaofei Bai,Shengqian Dou,Qingjun Zhou,Chao Wei,Bi Ning Zhang,Ting Wang,Weiyun Shi
DOI: https://doi.org/10.1002/adhm.202401179
IF: 10
2024-06-21
Advanced Healthcare Materials
Abstract:Keratomycosis, caused by pathogenic fungi, is an intractable blinding eye disease. Corneal penetration is an essential requirement for conventional antifungal medications to address keratomycosis. Due to the distinctive anatomical and physiological structure of the cornea, the therapeutic efficacy is hampered by the inadequate penetration capacity. Despite the emergence of diverse antifungal drug delivery systems and advanced antifungal nanomaterials, it has remained challenging to achieve corneal penetration over the past decade. In the study, we fabricated a penetrative ionic organic molecular cage‐based nanozyme (OMCzyme) for treating keratomycosis. The synthesis of OMCzyme involved two steps. Initially, the ionic OMC was synthesized by a [2+3] cycloimination reaction of triformylphloroglucinol and 2,3‐diaminopropionic acid. Subsequently, OMCzyme was fabricated by coordination of Fe2+ with carboxyl anions and phenolic hydroxyls in the organic cage, and further deposition of silver nanoparticles on the surface of OMC‐Fe complex. The as‐prepared OMCzyme demonstrated excellent water dispersion, peroxidase‐like activity, in vitro and in vivo biocompatibility, and corneal penetration. Notably, the nanozyme displayed targeted antifungal activity, effectively combating Fusarium solani with negligible cytotoxicity towards human corneal epithelial cells. The hybrid mimic was further demonstrated to be effective in treating keratomycosis in mice, indicating the potential of OMCzyme for curing fungal infectious diseases. This article is protected by copyright. All rights reserved
nanoscience & nanotechnology,engineering, biomedical,materials science, biomaterials